User menu

eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes

Bibliographic reference Hermans, Michel ; Ahn, Sylvie A ; Rousseau, Michel. eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes. In: European Journal of Clinical Investigation, Vol. 42, no.7, p. 729-737 (2012)
Permanent URL
  1. Arnal J.-F., Dinh-Xuan A.-T., Pueyo M., Darblade B., Rami J., Endothelium-derived nitric oxide and vascular physiology and pathology, 10.1007/s000180050358
  2. Kim J.-a, Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms, 10.1161/circulationaha.105.563213
  3. Huang Paul L., eNOS, metabolic syndrome and cardiovascular disease, 10.1016/j.tem.2009.03.005
  4. Shimokawa Hiroaki, Tsutsui Masato, Nitric oxide synthases in the pathogenesis of cardiovascular disease : Lessons from genetically modified mice, 10.1007/s00424-010-0796-2
  5. Dias Rodrigo Gonçalves, Gowdak Márcia Maria, Pereira Alexandre Costa, Genetics and cardiovascular system: influence of human genetic variants on vascular function, 10.1007/s12263-010-0193-7
  6. Markus H. S., Ruigrok Y., Ali N., Powell J. F., Endothelial Nitric Oxide Synthase Exon 7 Polymorphism, Ischemic Cerebrovascular Disease, and Carotid Atheroma, 10.1161/01.str.29.9.1908
  7. Hingorani A. D., Liang C. F., Fatibene J., Lyon A., Monteith S., Parsons A., Haydock S., Hopper R. V., Stephens N. G., O'Shaughnessy K. M., Brown M. J., A Common Variant of the Endothelial Nitric Oxide Synthase (Glu298->Asp) Is a Major Risk Factor for Coronary Artery Disease in the UK, 10.1161/01.cir.100.14.1515
  8. Schneider Markus P., Erdmann Jeanette, Delles Christian, Fleck Eckart, Regitz-Zagrosek Vera, Schmieder Roland E, Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase : , 10.1097/00004872-200018120-00010
  9. Colombo M G, Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298->Asp polymorphism) to the presence, extent, and severity of coronary artery disease, 10.1136/heart.87.6.525
  10. Chrysohoou Christine, Panagiotakos Demosthenes B., Pitsavos Christos, Antoniades Charalambos, Skoumas John, Brown Michael, Stefanadis Christodoulos, Evidence for association between endothelial nitric oxide synthase gene polymorphism (G894T) and inflammatory markers: The ATTICA study, 10.1016/j.ahj.2004.04.022
  11. Hassan A., Endothelial Nitric Oxide Gene Haplotypes and Risk of Cerebral Small-Vessel Disease, 10.1161/01.str.0000117238.75736.53
  12. Jaramillo Priscilla C., Muñoz M. Alvaro, Lanas M. Cecilia, Lanas Z. Fernando, Salazar Luis A., Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls, 10.1016/j.cca.2006.02.030
  13. Tso Annette W.K., Tan Kathryn C.B., Wat Nelson M.S., Janus Edward D., Lam Tai-Hing, S.L. Lam Karen, Endothelial nitric oxide synthase G894T (Glu298Asp) polymorphism was predictive of glycemic status in a 5-year prospective study of Chinese subjects with impaired glucose tolerance, 10.1016/j.metabol.2006.04.012
  14. Bhuiyan Azad R., Chen Wei, Srinivasan Sathanur R., Rice Janet, Mock Nancy, Tang Rong, Bond M. Gene, Boerwinkle Eric, Berenson Gerald S., Influence of nitric oxide synthase gene polymorphism (G894T) on carotid artery intima-media thickness in adults: the Bogalusa Heart Study, 10.1016/j.jash.2007.06.006
  15. Godfrey Valerie, Chan Sue-Lyn, Cassidy Andrew, Butler Robert, Choy AnnaMaria, Fardon Tom, Struthers Allan, Lang Chim, The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers, 10.1111/j.1527-3466.2007.00017.x
  16. Eisenhardt A., Stief C., Porst H., Wetterauer U., Weidner W., Rübben H., Sperling H., Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population : Genetic association and ED, 10.1111/j.1439-0272.2009.00975.x
  17. Hermans Michel P, Fruchart Jean-Charles, Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?, 10.2217/clp.10.65
  18. Hermans Michel P., Amoussou-Guenou K. Daniel, Ahn Sylvie A., Rousseau Michel F., Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes, 10.1016/j.dsx.2010.05.021
  19. Hermans Michel P., Fruchart Jean-Charles, Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians, 10.1177/2040622311413952
  20. Hermans, Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications, 45 (2011)
  21. Rosas-Vargas Haydee, Coral-Vazquez Ramon M., Tapia Rosario, Borja Jose L., Salas Ricardo A., Salamanca Fabio, Glu298Asp Endothelial Nitric Oxide Synthase Polymorphism Is a Risk Factor for Erectile Dysfunction in the Mexican Mestizo Population, 10.1002/j.1939-4640.2004.tb02847.x
  22. Musicki B., Kramer M. F., Becker R. E., Burnett A. L., Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction, 10.1073/pnas.0502488102
  23. Burnett Arthur L., The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy, 10.1111/j.1524-6175.2006.06026.x
  24. Andersen Monica L., Guindalini Camila, Santos-Silva Rogerio, Bittencourt Lia Rita A., Tufik Sergio, Association Analysis of Endothelial Nitric Oxide Synthase G894T Gene Polymorphism and Erectile Dysfunction Complaints in a Population-Based Survey, 10.1111/j.1743-6109.2009.01606.x
  25. Wang Jia-Li, Wang Hai-Gang, Gao Hai-Qing, Zhai Guang-Xi, Chang Ping, Chen Yu-Guo, Endothelial Nitric Oxide Synthase Polymorphisms and Erectile Dysfunction: A Meta-Analysis, 10.1111/j.1743-6109.2010.01968.x
  26. Safarinejad Mohammad Reza, Khoshdel Alireza, Shekarchi Babak, Taghva Arsia, Safarinejad Shiva, Association of the T-786C, G894T and 4a/4b polymorphisms of the endothelial nitric oxide synthase gene with vasculogenic erectile dysfunction in Iranian subjects : ENOS GENE POLYMORPHISMS AND ERECTILE DYSFUNCTION, 10.1111/j.1464-410x.2010.09755.x
  27. TODA N, NAKANISHITODA M, Nitric oxide: Ocular blood flow, glaucoma, and diabetic retinopathy, 10.1016/j.preteyeres.2007.01.004
  28. Varma Shambhu D., Hegde Kavita R., Susceptibility of the Ocular Lens to Nitric Oxide: Implications in Cataractogenesis, 10.1089/jop.2006.0124
  29. , Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 10.2337/diacare.20.7.1183
  30. Valdez, Int J Obes, 16, 77 (1992)
  31. Kyle Ursula G, Morabia Alfredo, Schutz Yves, Pichard Claude, Sedentarism affects body fat mass index and fat-free mass index in adults aged 18 to 98 years, 10.1016/j.nut.2003.11.019
  32. Burkhauser Richard V., Cawley John, Beyond BMI: The value of more accurate measures of fatness and obesity in social science research, 10.1016/j.jhealeco.2007.05.005
  33. Kothari V., Stevens R. J., Adler A. I., Stratton I. M., Manley S. E., Neil H. A., Holman R. R., UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine, 10.1161/01.str.0000020091.07144.c7
  34. Stevens R. J., Coleman R. L., Adler A. I., Stratton I. M., Matthews D. R., Holman R. R., Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66, 10.2337/diacare.27.1.201
  35. Hermans M.P., Ahn S.A., Rousseau M.F., Statin therapy and cataract in type 2 diabetes, 10.1016/j.diabet.2010.09.005
  36. Saaddine Jinan B., Projection of Diabetic Retinopathy and Other Major Eye Diseases Among People With Diabetes Mellitus : United States, 2005-2050, 10.1001/archopht.126.12.1740
  37. Hermans Michel P., Ahn Sylvie A., Rousseau Michel F., Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes, 10.1016/j.diabet.2009.06.003
  38. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males, 10.1186/1475-2840-9-88
  39. Hermans Michel P., Ahn Sylvie A., Gruson Damien, Rousseau Michel F., The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes, 10.1016/j.dsx.2007.09.001
  40. Levey Andrew S., A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, 10.7326/0003-4819-130-6-199903160-00002
  41. Grundy S. M., Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, 10.1161/circulationaha.105.169404
  42. Levy J. C., Matthews D. R., Hermans M. P., Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program, 10.2337/diacare.21.12.2191
  43. Hermans M. P., Levy J. C., Morris R. J., Turner R. C., Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes, 10.1007/s001250051215
  44. Munoko Thierry N., Hermans Michel P., Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes, 10.1016/j.dsx.2008.02.004
  45. Hackett Dr Geoff, Hypertensive Medication and Erectile Dysfunction, 10.1111/j.1755-5922.2009.00130.x
  46. Cordero Alberto, Bertomeu-Martínez Vicente, Mazón Pilar, Fácila Lorenzo, Bertomeu-González Vicente, Conthe Pedro, González-Juanatey José Ramón, Erectile Dysfunction in High-Risk Hypertensive Patients Treated with Beta-Blockade Agents, 10.1111/j.1755-5922.2009.00123.x
  47. Park J K, Kim W, Kim S W, Koh G Y, Park S K, Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with erectile dysfunction, 10.1038/sj.ijir.3900437
  48. Bron A., Baudouin C., Nordmann J.-P., Rouland J.-F., Thomas F., Bean K., De Clercq B., Bénétos A., Solesse de Gendre A., Lefebvre S., Prévalence de l’hypertonie oculaire et du glaucome dans une population française non sélectionnée, 10.1016/s0181-5512(06)73824-4
  49. Macdonald M J, Cullen P M, Phillips C I, Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose., 10.1136/bjo.60.11.789